等待开盘 09-19 09:30:00 美东时间
+3.730
+2.86%
今日重点评级关注:HC Wainwright & Co.:维持Microbot Medical"买入"评级,目标价从9美元升至12美元;Maxim Group:维持Neuphoria Therapeutics"买入"评级,目标价从18美元升至35美元
09-12 12:53
Barrington Research analyst Vincent Colicchio maintains Climb Global Solutions (NASDAQ:CLMB) with a Outperform and maintains $136 price target.
09-11 20:08
Climb Bio announces a webcast event on September 29, 2025, featuring its CLYM116 program, a novel anti-APRIL monoclonal antibody targeting IgA nephropathy. The event will include an overview of IgAN, preclinical data comparing CLYM116 to existing treatments, and the company's development strategy. CLYM116 employs a unique 'sweeper' mechanism, potentially offering best-in-class efficacy with less frequent dosing. The webcast will be accessible via...
09-04 11:00
Climb Channel Solutions, a global specialty technology distributor and subsidiary of Climb Global Solutions (NASDAQ: CLMB), has announced a North American distribution partnership with Forcepoint, a global leader in data security. This strategic alliance combines Climb's channel expertise with Forcepoint's AI-native, unified data security platform, enabling organizations to safeguard sensitive information, adapt to changing risks, and support sec...
09-03 11:00
Climb Channel Solutions, a global technology distributor, partners with Coro to deliver comprehensive cybersecurity solutions, leveraging Coro's unified platform to protect against email threats, endpoint attacks, and data loss. The partnership enhances Climb's cybersecurity portfolio and supports growth for SMBs and distributed enterprises. Both companies aim to simplify cybersecurity delivery for partners, enabling scalable and profitable busin...
08-26 11:00
Climb Bio, a clinical-stage biotechnology company, announced that its executives will participate in several upcoming investor conferences in New York and virtually. The events include the Cantor Global Healthcare Conference on September 5, the Baird Global Healthcare Conference on September 9, the Morgan Stanley Global Healthcare Conference on September 10, and the Stifel Virtual Immunology and Inflammation Forum on September 10. Live webcasts a...
08-25 11:00
Climb Bio reported Q2 2025 financial results, highlighting progress with its lead product budoprutug in clinical trials for immune thrombocytopenia (ITP), systemic lupus erythematosus (SLE), and primary membranous nephropathy (pMN). The company also announced plans to initiate a Phase 2 trial for pMN and a Phase 1 trial for the subcutaneous formulation of budoprutug. CLYM116, targeting IgA nephropathy (IgAN), is advancing toward clinical developm...
08-12 11:00
Climb stock is up over 240% since mid-2023, Adhishthana principles show a classic Phase 9 breakout. Here's what investors need to know next.
07-29 20:17
今日重点评级关注:Canaccord Genuity:维持Mobileye Global"买入"评级,目标价从25美元升至30美元;巴克莱:维持TechnipFMC"超配"评级,目标价从45美元升至51美元
07-28 09:33
Barrington Research analyst Vincent Colicchio maintains Climb Global Solutions (NASDAQ:CLMB) with a Outperform and maintains $136 price target.
07-26 01:47